A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

 Supported by the NIH/National Cancer Institute (grants R01 CA121210, P01 CA129243, U54 CA143798, CA102353, and RC2-CA148394-01), the VICC Specialized Program of Research Excellence in Lung Cancer grant (CA90949), the Vanderbilt-Ingram Cancer Center Core grant (CA68485), the V Foundation, the TJ Martell Foundation, the Kleberg Foundation, and an anonymous donor.

 D.D.-S. and A.J.I. submitted a patent application for the SNaPshot genotyping methods described herein, which are the subject of licensing discussions; W.P. was a consultant for MolecularMD, and rights to EGFR T790M testing were licensed on behalf of W.P. and others by the Memorial Sloan-Kettering Cancer Center to MolecularMD.

 Supplemental material for this article can be found at http://jmd.amjpathol.org and at doi:10.1016/j.jmoldx.2010.11.010.

 Current address of C.H.C.: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

PII: S1525-1578(10)00024-3

doi: 10.1016/j.jmoldx.2010.11.010

© 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.